CSPC Pharmaceutical Group Ltd. has announced that its Meloxicam Injection $(III.UK)$ has received drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is indicated for the treatment of moderate to severe pain in adults and is the first intravenously administered nanocrystal product approved in China. Utilizing novel nanotechnology, this formulation allows for high-dose, rapid intravenous administration, offering a rapid onset and long-lasting analgesic effects for acute postoperative pain. This approval marks a significant advancement for CSPC in the field of nanomedicine research and development.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。